167090-40-6Relevant articles and documents
Process development in the synthesis of the ACE intermediate MDL 28,726
Horgan, Stephen W.,Burkhouse, David W.,Cregge, Robert J.
, p. 241 - 247 (1999)
MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed resolution of the lithium salt of the W-trifluoroacetamide of (A,5)-6-hydroxynorleucine. All of the steps were optimized and completed in reactor equipment using environmentally acceptable processes. Process development of this route is described.
Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof
-
, (2011/02/18)
The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions
A novel three-step hydroxy-deamination sequence: Conversion of lysine to 6-hydroxynorleucine derivatives
Nevill Jr., C. Richard,Angell, Paul T.
, p. 5671 - 5674 (2007/10/03)
Oxidation of carbamates with catalytic RuO4, generated from RuO2 and NaBrO3, provides the corresponding acyl carbamates, which can be reduced with NaBH4 to provide alcohols. Application of this methodology to L-lysine provides (S)-6-hydroxynorleucine derivatives.
